Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats

Canadian Journal of Physiology and Pharmacology

Volumn 89, Issue 4, 2011, Pages 269-276

  Ammar, El Sayed M ^a   Said, Shehta A ^a   Suddek, Ghada M ^a   El Damarawy, Sally L ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Aconitine; Cardiotoxicity; Deferiprone; Doxorubicin; Ecg

Indexed keywords

ACONITINE; CREATINE KINASE MB; DEFERIPRONE; DOXORUBICIN; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE REDUCTION; ECG ABNORMALITY; ENZYME ACTIVITY; HEART MUSCLE; HEART PROTECTION; HEART RATE; HEART VENTRICLE TACHYCARDIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QT INTERVAL; RAT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; T WAVE AMPLITUDE;

ACONITINE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CREATINE KINASE, MB FORM; DOXORUBICIN; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; GLUTATHIONE; HEART; HEART DISEASES; HEART RATE; IRON; IRON CHELATING AGENTS; L-LACTATE DEHYDROGENASE; MALE; MALONDIALDEHYDE; MYOCARDIUM; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TACHYCARDIA, VENTRICULAR;

EID: 79960767791     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/y11-020     Document Type: Article

References (44)

1. Ahmed, H.H., Mannaa, F., Elmegeed, G.A., and Doss, S.H. 2005. Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity. Bioorg. Med. Chem. 13(5): 1847-1857. doi:10.1016/j.bmc.2004.10.066.
2. Anderson, L.J., Wonke, B., Prescott, E., Holden, S.,Walker, J.M., and Pennell, D.J. 2002. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in b-thalassaemia. Lancet, 360(9332): 516-520. doi:10.1016/S0140-6736(02)09740-4.
3. Barnabé, N., Zastre, J.A., Venkataram, S., and Hasinoff, B.B. 2002. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic. Biol. Med. 33(2): 266-275. doi:10.1016/ S0891-5849(02)00873-0.
4. Bazett, H.C. 1920. An analysis of time relations of electrocardiograms. Heart, 7: 353-367.
5. Beutler, E., Duron, O., and Kelly, B.M. 1963. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 61: 882-888.
6. Cirillo, R., Sacco, G., Venturella, S., Brightwell, J., Giachetti, A., and Manzini, S. 2000. Comparison of doxorubicin- and MEN 10755- induced long-term progressive cardiotoxicity in the rat. J. Cardiovasc. Pharmacol. 35(1): 100-108. doi:10.1097/00005344-200001000-00013.
7. Danesi, R., Bernardini, N., Agen, C., Costa, M., Macchiarini, P., Della Tore, P., and Del Tacca, M. 1991. Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin. Toxicology, 70(2): 243-253. doi:10.1016/0300-483X(91)90050-B.
8. Daniel, W.W. 1991. Hypothesis testing. In Biostatistics: a foundation for analysis in the health sciences. 5th ed. Edited by W.W. Daniel. John Wiley & Sons, New York. p. 191.
9. Dragojevic-Simic, V.M., Dobric, S.L., Bokonjic, D.R., Vucinic, Z.M., Sinovec, S.M., Jacevic, V.M., and Dogovic, N.P. 2004. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs, 15(2): 169-178. doi:10.1097/00001813-200402000-00011.
10. El-Shitany, N.A., El-Haggar, S., and El-desoky, K. 2008. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem. Toxicol. 46(7): 2422-2428. doi:10.1016/j.fct.2008.03.033.
11. Gan, T.E., Ellims, P.H., Tong, N., Barned, J.M., and Van der Weyden, M.B. 1983. Doxorubicin-associated delayed ventricular fibrillation in acute promyelocytic leukemia. Acta Haematol. 69(1): 52-55. doi:10.1159/000206839.
12. Gianni, L., and Myers, C. 1992. The role of free radical formation in the cardiotoxicity of anthracyclines. In Cancer treatment and the heart. 1st ed. Edited by F.M. Muggia, M.D. Green, and J.L. Speyer. Johns Hopkins University Press, Baltimore, Md. pp. 9-46.
13. Glickstein, H., El, R.B., Link, G., Breuer, W., Konijn, A.M., Hershko, C., et al. 2006. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood, 108(9): 3195-3203. doi:10.1182/blood-2006-05-020867.
14. Goldberger, A.L., and Goldberger, E. 1994. Ventricular arrhythmias. In Clinical electrocardiography. A simplified approach. 5th ed. Edited by S. Manning, C. Malik, and G.B. Stericker. Elsevier Mosby, New York. pp. 177-191.
15. Gryglewski, R.J., Palmer, M.J., and Moncada, S. 1986. Superoxide anion is involved in the breakdown of endothelium derived vascular relaxing factor. Nature (Lond.), 320(6061): 454-456. doi:10.1038/320454a0.
16. Henry, R.J. 1974. Colorimetric determination of lactic dehydrogenase. In Clinical chemistry: principles and techniques. Edited by R.J. Henry. 2nd ed. Harper and Row, Hagerstown, Md. pp. 819-831.
17. Kaneko, M., Matsumoto, Y., Hayashi, H., Kobayashi, A., and Yamazaki, N. 1994. Oxygen free radicals and calcium homeostasis in the heart. Mol. Cell. Biochem. 139(1): 91-100. doi:10.1007/BF00944207.
18. Kilickap, S., Akgul, E., Aksoy, S., Aytemir, K., and Barista, I. 2005. Doxorubicin-induced second degree and complete atrioventricular block. Europace, 7(3): 227-230. doi:10.1016/j.eupc.2004.12.012.
19. Kontoghiorghes, G.J., Pattichis, K., Neocleous, K., and Kolnagou, A. 2004. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr. Med. Chem. 11(16): 2161-2183.
20. + channels in rat coronary microvessels exposed to high glucose. Diabetes, 53(9): 2436-2442. doi:10.2337/diabetes.53.9.2436.
21. Link, G., Tirosh, R., Pinson, A., and Hershko, C. 1996. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 127(3): 272-278. doi:10.1016/S0022-2143(96)90095-5.
22. Liu, X., Chen, Z., Chua, C.C., Ma, Y.S., Youngberg, G.A., Hamdy, R., and Chua, B.H. 2002. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 283(1): H254-H263.
23. Marklund, S., and Marklund, G. 1974. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 47(3): 469-474. doi:10.1111/j.1432-1033.1974.tb03714.x.
24. Milberg, P., Fleischer, D., Stypmann, J., Osada, N., Mönnig, G., Engelen, M.A., et al. 2007. Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by IKr blockers. Basic Res. Cardiol. 102(1): 42-51. doi:10.1007/s00395-006-0609-0.
25. Mukherjee, S., Banerjee, S.K., Maulik, M., Dinda, A.K., Talwar, K. K., and Maulik, S.K. 2003. Protection against acute adriamycininduced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-a expression. BMC Pharmacol. 3(1): 16.doi:10.1186/1471-2210-3-16.
26. Nousiainen, T., Vanninen, E., Rantala, A., Jantunen, E., and Hartikainen, J. 1999. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J. Intern. Med. 245(4): 359-364. doi:10.1046/j.1365-2796.1999.00480.x.
27. Ohkawa, H., Ohishi, N., and Yagi, K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95(2): 351-358. doi:10.1016/0003-2697(79)90738-3.
28. Olivieri, N.F., Koren, G., Matsui, D., Liu, P.P., Blendis, L., Cameron, R., et al. 1992. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood, 79(10): 2741-2748.
29. Outomuro, D., Grana, D.R., Azzato, F., and Milei, J. 2007. Adriamycin-induced myocardial toxicity: new solutions for an old problem. Int. J. Cardiol. 117(1): 6-15. doi:10.1016/j.ijcard.2006.05.005.
30. Rao, G.N., Runge, M.S., and Alexander, R.W. 1995. Hydrogen peroxide activation of cytosolic phospholipase A2 in vascular smooth muscle cells. Biochim. Biophys. Acta, 1265(1): 67-72. doi:10.1016/0167-4889(95)91997-Z.
31. Rudzinski, T., Ciesielczyk, M., Religa, W., Bednarkiewicz, Z., and Krzeminska-Pakula, M. 2007. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverterdefibrillator. Europace, 9(5): 278-280. doi:10.1093/europace/eum033.
32. Salvemini, F., Franzé, A., Iervolino, A., Filosa, S., Salzano, S., and Ursini, M.V. 1999. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J. Biol. Chem. 274(5): 2750-2757. doi:10.1074/jbc.274.5.2750
33. Shan, K., Lincoff, A.M., and Young, J.B. 1996. Anthracyclineinduced cardiotoxicity. Ann. Intern. Med. 125(1): 47-58.
34. Tokarska-Schlattner, M., Zaugg, M., Da Silva, R., Lucchinetti, E., Schaub, M.C., Wallimann, T., and Schlattner, U. 2005. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am. J. Physiol. Heart Circ. Physiol. 289(1): H37-H47. doi:10.1152/ajpheart.01057.2004.
35. Venkatesan, N. 1998. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br. J. Pharmacol. 124(3): 425-427. doi:10.1038/sj.bjp.0701877.
36. Von Hoff, D.D., Rozencweig, M., Layard, M., Slavik, M., and Muggia, F.M. 1977. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. 62(2): 200-208. doi:10.1016/0002-9343(77)90315-1.
37. Wakade, A.S., Shah, A.S., Kulkarni, M.P., and Juvekar, A.R. 2008. Protective effect of Piper longum L. on oxidative stress induced injury and cellular abnormality in adriamycin induced cardiotoxicity in rats. Indian J. Exp. Biol. 46(7): 528-533.
38. Wortman, J.E., Lucas, V.S., Jr, Schuster, E., Thiele, D., and Logue, G. L. 1979. Sudden death during doxorubicin administration. Cancer, 44(5): 1588-1591. doi:10.1002/1097-0142(197911)44:5<1588::AID-CNCR2820440508>3.0.CO;2-X.
39. Würzburg, U., Hennrich, N., Orth, H.D., Lang, H., Prellwitz, W., Neumeier, D., et al. 1977. Quantitative determination of creatine kinase isoenzyme catalytic concentrations in serum using immunological methods. J. Clin. Chem. Clin. Biochem. 15(3): 131-137.
40. Xu, X., Persson, H.L., and Richardson, D.R. 2005. Molecular pharmacology of the interaction of anthracyclines with iron. Mol. Pharmacol. 68(2): 261-271.
41. Xu, L.J., Jin, L., Pan, H., Zhang, A.Z., Wei, G., Li, P.P., and Lu, W.Y. 2006. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol. Sin. 27(10): 1333-1339. doi:10.1111/j.1745-7254.2006.00409.x.
42. Yilmaz, S., Atessahin, A., Sahna, E., Karahan, I., and Ozer, S. 2006. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology, 218(2-3): 164-171. doi:10.1016/j.tox.2005.10.015.
43. Young, R.C., Ozols, R.F., and Myers, C.E. 1981. The anthracycline antineoplastic drugs. N. Engl. J. Med. 305(3): 139-153. doi:10.1056/NEJM198107163050305.
44. Zhang, X.Y., Li, W.G., Wu, Y.J., and Gao, M.T. 2005. Amelioration of doxorubicin-induced myocardial oxidative stress and immunosuppression by grape seed proanthocyanidins in tumour-bearing mice. J. Pharm. Pharmacol. 57(8): 1043-1051. doi:10.1211/0022357056523.